Accessibility Menu
NovaBridge Biosciences logo

NovaBridge Biosciences(NASDAQ) IMAB

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-85%
5 Year-97%
1 Year-63%
1 Month+7%
N/A
NovaBridge Biosciences last closing stock price
MetricPriceDate
Last closeUSD 1.892026-08-24
NovaBridge Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.07%USD 1.932026-08-17
1 month+6.78%USD 1.772026-07-24
3 month+1.61%USD 1.862026-05-26
Year to date-52.51%USD 3.982025-12-31
1 year-62.87%USD 5.092025-08-22
3 year+0.53%USD 1.882023-08-25
5 year-97.21%USD 67.712021-08-25
Since inception-84.88%USD 12.502020-01-17

NovaBridge Biosciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$5.36M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 12, 2025

IMAB News

GettyImages-647334054

AbbVie Partners With I-Mab for Cancer Drug

Jim CrumlySep 4, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NovaBridge Biosciences

I-Mab is a biopharmaceutical company focused on the discovery, development, and commercialization of biologic therapies. The company aims to address significant medical needs in oncology and autoimmune diseases through a robust pipeline of innovative drug candidates.

Products and Services
  • Eftansomatropin alfa for pediatric growth hormone deficiency
  • Lemzoparlimab, a CD47 monoclonal antibody for cancer treatment
  • Felzartamab, a CD38 antibody for membranous nephropathy
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Strategic partnerships with industry leaders enhance development capabilities
  • Focus on addressing unmet medical needs in oncology and autoimmune diseases
Financial Highlights
  • Recent quarterly net income of -$767,532, reflecting ongoing investment in R&D
  • Cash and short-term investments totaled $165.6 million as of June 30, 2025
  • Current ratio of 8.09 indicates strong liquidity position
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

30

CEO

Xi-Yong Fu, PhD, MBA

Website

www.i-mabbiopharma.com

Headquarters

Rockville, 200124, US

IMAB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-0.59%

Return on Capital

-25.07%

Return on Assets

-53.39%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$5.32M

EBITDA

-$4.29M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$165.61M

Total Debt

$3.48M

NovaBridge Biosciences Performance Analysis

NovaBridge Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD -32,903,536N/A
20232023-12-31USD 631,451N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
NovaBridge Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31N/A
Q22025-06-30N/A
NovaBridge Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.51-5.2%
20232023-12-31USD -2.49-44.7%
20242024-12-31USD -0.70-72.0%
20252025-12-31USD -0.48-30.5%
NovaBridge Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30-187.7%
Q42024-12-3158.0%
Q12025-03-31-154.5%
Q22025-06-3075.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

32

N/A

Net Income

-$767.53K

-122.2%

EBITDA

-$992.05K

+93.0%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$165.61M

-20.2%

Total Debt

$3.48M

+539.0%

Accounts Receivable

$2.03M

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.63M

-18.4%

Short Term Debt

$853.00K

+741.1%

Return on Assets

-53.39%

N/A

Return on Invested Capital

-95.18%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALXOALX Oncology Holdings Inc.
$2.00+0.50%
BNRBurning Rock Biotech Limited
$9.80-5.04%
CCCCC4 Therapeutics, Inc.
$4.20+2.44%
CGEMCullinan Therapeutics, Inc.
$22.95+5.18%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$213.05+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.09+0.01%
INTCIntel
$87.48+0.00%
BITOProShares Trust - ProShares Bitcoin ETF
$10.66+0.00%

Questions About IMAB

What is the current price of NovaBridge Biosciences?

NovaBridge Biosciences is trading at N/A per share.

What is the 52-week range for NovaBridge Biosciences?

Over the past 52 weeks, NovaBridge Biosciences has traded between N/A and N/A.

How much debt does NovaBridge Biosciences have?

As of the most recent reporting period, NovaBridge Biosciences reported total debt of $3.07M.

How much cash does NovaBridge Biosciences have on hand?

NovaBridge Biosciences reported $210.63M in cash and cash equivalents in its most recent financial results.

What is NovaBridge Biosciences’s dividend yield?

NovaBridge Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services